Diabetic Nephropathies Clinical Trial
Official title:
A Prospective, Open, Multicenter, Clinical Study of Huangqi Guizhi Wuwu Decoction in Treating Diabetic Nephropathy (Stage CKD2-4)
This is a prospective, open, multicenter clinical trial.The objective of this study is to evaluate the efficacy and safety of Huangqi Guizhi Wuwu Decoction in patients with CKD stage 2-4 diabetic nephropathy.
The incidence rate of chronic kidney disease is 10.8% in China. The incidence rate of diabetic nephropathy has increased year by year, and now it has become the first cause of uremia. Therefore, the treatment of diabetic nephropathy can delay the progression of renal function and is of great value and significance in reducing uremia. Huangqi Guizhi Wuwu decoction is a traditional Chinese medicine decoction. Previous studies have shown that it is effective in the treatment of diabetic nephropathy. In this study, there were 2 hospitals participating in. We planned to enroll 100 participants, who will be divided into the Huangqi Guizhi Wuwu decoction group (experimental group) and the Dapagliflozin group (control group). All participants will take medication for 12 weeks, and investigators will follow up participates at weeks 0, 2,4, 6, 8,12. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
| Terminated |
NCT01575379 -
A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
|
Phase 4 | |
| Active, not recruiting |
NCT05656963 -
The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
|
||
| Not yet recruiting |
NCT04084886 -
TCF7L2 Gene Polymorphism and AGEs in Diabetic Nephropathy
|
||
| Active, not recruiting |
NCT04869761 -
Stem Cell Therapy for Chronic Kidney Disease
|
Phase 1 | |
| Recruiting |
NCT04570735 -
MRI Biomarkers in Diabetic Kidney Disease
|
||
| Completed |
NCT03165240 -
This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated
|
Phase 1 | |
| Completed |
NCT01968668 -
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)
|
Phase 2 | |
| Completed |
NCT02552277 -
A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy
|
Phase 2 | |
| Terminated |
NCT03840343 -
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
|
Phase 1 | |
| Terminated |
NCT02410005 -
Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)
|
Phase 2/Phase 3 | |
| Unknown status |
NCT01918488 -
Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease
|
N/A | |
| Completed |
NCT00915200 -
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
|
Phase 2 | |
| Completed |
NCT03165227 -
This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)
|
Phase 1 | |
| Active, not recruiting |
NCT04531163 -
Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03620773 -
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
|
Phase 1/Phase 2 | |
| Completed |
NCT03618420 -
Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03284996 -
Doppler Ultrasound in Early Detection of Diabetic Nephropathy Type 2 Diabetes Mellitus.
|
N/A | |
| Completed |
NCT03334318 -
PERL Continuous Glucose Monitoring (CGM) Study
|
||
| Completed |
NCT04380584 -
Relation Between Plasma Apelin Level and Diabetic Nephropathy in Type 2 Diabetes Patients.
|